Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mazaticol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 19/20 | 0.50 |
| ▸ | CHRM2 known ✓ | P08172 | 14/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 12/20 | 0.48 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.48 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.48 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.48 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.48 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.48 |
| ▸ | TSPO | P30536 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mazaticol SCHEMBL17747972 | 0.99 | CHRM3 (0.50) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Mazaticol SCHEMBL34619 | 0.99 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4886984 | 0.85 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4886970 | 0.85 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4886957 | 0.85 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Mazaticol SCHEMBL15229491 | 0.83 | ADRA1A (0.39) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Mazaticol SCHEMBL28086106 | 0.79 | CHRM3 (0.34) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL16742011 | 0.76 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1900207 | 0.76 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL14472825 | 0.76 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829116-B2 | Silylated polyurethanes; pressure sensitive adhesives; transdermal drug delivery | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2010-11-09 | — | — | US | claimed |
| CN-101563381-A | Adhesive forming compositions and adhesive blends obtained therefrom | MOMENTIVE PERFORMANCE MAT INC (US) | 2009-10-21 | — | — | CN | claimed |
| EP-2104695-A2 | ADHESIVE-FORMING COMPOSITION AND BLEND OF ADHESIVES OBTAINED THEREFROM | Momentive Performance Materials Inc. (US) | 2009-09-30 | — | — | EP | claimed |
| WO-2008060506-A2 | ADHESIVE-FORMING COMPOSITION AND BLEND OF ADHESIVES OBTAINED THEREFROM | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2008-05-22 | — | — | WO | claimed |
| US-20080114098-A1 | Adhesive-forming composition and blend of adhesives obtained therefrom | GENERAL ELECTRIC COMPANY (US) | 2008-05-15 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-3556771-B1 | ANTI-CLAUDIN 5 ANTIBODY, AND MEDICINE CONTAINING SAID ANTIBODY | UNIV OSAKA (JP) | 2024-10-02 | — | — | EP | disclosed |
| US-11053313-B2 | Anti-CLDN-5 antibody, and drug containing said antibody | OSAKA UNIVERSITY (JP) | 2021-07-06 | — | — | US | disclosed |
| US-10882906-B2 | Claudin 5 antibody, and medicine containing said antibody | OSAKA UNIVERSITY (JP) | 2021-01-05 | — | — | US | disclosed |
| US-20200223915-A1 | Claudin 5 ANTIBODY, AND MEDICINE CONTAINING SAID ANTIBODY | OSAKA UNIVERSITY (JP) | 2020-07-16 | — | — | US | disclosed |
| US-20200148765-A1 | ANTI-CLDN-5 ANTIBODY, AND DRUG CONTAINING SAID ANTIBODY | OSAKA UNIVERSITY (JP) | 2020-05-14 | — | — | US | disclosed |
| EP-3623384-A1 | ANTI-CLDN-5 ANTIBODY, AND DRUG CONTAINING SAID ANTIBODY | Osaka University (JP) | 2020-03-18 | — | — | EP | disclosed |
| EP-3556771-A1 | CLAUDIN 5 ANTIBODY, AND MEDICINE CONTAINING SAID ANTIBODY | Osaka University (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-5556636-A | Adhesive composition for medical use | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0482554-B1 | Transdermal Drug Delivery Preparation | KANEGAFUCHI CHEMICAL IND (JP) | 1995-09-20 | — | — | EP | disclosed |
| EP-0452837-B1 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORP (JP) | 1995-08-16 | — | — | EP | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| US-5176916-A | Plaster layer containing a medicinal ingredient, hydrophobic polymer, absorption promoter, water and a hydrophilic polymer | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0482554-A2 | Transdermal Drug Delivery Preparation | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-04-29 | — | — | EP | disclosed |
| EP-0452837-A2 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORPORATION (JP) | 1991-10-23 | — | — | EP | disclosed |